Latham, Wachtell Lead on $25 Billion Actavis-Forest Labs Deal

, The Am Law Daily

   | 0 Comments

Dublin-based generic drug maker Actavis is buying Forest Laboratories in a $25 billion cash-and-stock deal that increases Actavis' access to specialty drugs. Latham is advising longtime client Actavis on the deal, while Forest has turned to Wachtell. Other firms working on the deal include Skadden, which is counseling Actavis on antitrust issues, as well as Fried Frank and Simpson Thacher, which are representing financial advisers Greenhill & Co. and J.P. Morgan, respectively.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202643523218

Thank you!

This article's comments will be reviewed.